Junshi Biosciences Reports the P-III Trial Data of Toripalimab Plus Bevacizumab to Treat Advanced Hepatocellular Carcinoma (HCC)
Shots:
- The P-III (HEPATORCH) trial assesses the safety & efficacy of toripalimab + bevacizumab vs sorafenib (SoC) as a 1L treatment of unresectable or metastatic hepatocellular carcinoma HCC
- The study reached its 1EP, demonstrating prolonged PFS & OS with the combination vs sorafenib along with improvement in 2EPs of ORR & time to progression. The safety profile was favorable without any new safety concerns; data will be highlighted at future conferences with an sNDA for the same anticipated in the future
- Toripalimab, an anti-PD-1 mAb, works by preventing PD-1 interactions with PD-L1 & PD-L2 for improved tumor destruction and enhanced receptor internalization (endocytosis function)
Ref: Junshi Biosciences | Image: Junshi Biosciences
Related News:- Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (NPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
